BKM120 Combined with Vemurafenib (PLX4032)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF Mutant Metastatic Melanoma
Conditions
BRAF Mutant Metastatic Melanoma
Trial Timeline
Jun 9, 2012 → Mar 21, 2017
NCT ID
NCT01512251About BKM120 Combined with Vemurafenib (PLX4032)
BKM120 Combined with Vemurafenib (PLX4032) is a phase 1/2 stage product being developed by Novartis for BRAF Mutant Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01512251. Target conditions include BRAF Mutant Metastatic Melanoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512251 | Phase 1/2 | Completed |
Competing Products
13 competing products in BRAF Mutant Metastatic Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 52 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 52 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 23 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 25 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |